CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells
Open Access
- 15 September 2020
- journal article
- research article
- Published by Springer Nature in Cell Death & Disease
- Vol. 11 (9) , 1-14
Abstract
The identification of the essential role of cyclin-dependent kinases (CDKs) in the control of cell division has prompted the development of small-molecule CDK inhibitors as anticancer drugs. For many of these compounds, the precise mechanism of action in individual tumor types remains unclear as they simultaneously target different classes of CDKs – enzymes controlling the cell cycle progression as well as CDKs involved in the regulation of transcription. CDK inhibitors are also capable of activating p53 tumor suppressor in tumor cells retaining wild-type p53 gene by modulating MDM2 levels and activity. In the current study, we link, for the first time, CDK activity to the overexpression of the MDM4 (MDMX) oncogene in cancer cells. Small-molecule drugs targeting the CDK9 kinase, dinaciclib, flavopiridol, roscovitine, AT-7519, SNS-032, and DRB, diminished MDM4 levels and activated p53 in A375 melanoma and MCF7 breast carcinoma cells with only a limited effect on MDM2. These results suggest that MDM4, rather than MDM2, could be the primary transcriptional target of pharmacological CDK inhibitors in the p53 pathway. CDK9 inhibitor atuveciclib downregulated MDM4 and enhanced p53 activity induced by nutlin-3a, an inhibitor of p53-MDM2 interaction, and synergized with nutlin-3a in killing A375 melanoma cells. Furthermore, we found that human pluripotent stem cell lines express significant levels of MDM4, which are also maintained by CDK9 activity. In summary, we show that CDK9 activity is essential for the maintenance of high levels of MDM4 in human cells, and drugs targeting CDK9 might restore p53 tumor suppressor function in malignancies overexpressing MDM4.Keywords
Funding Information
- Grantová Agentura České Republiky (GA14-12166S, GA14-12166S, GA14-12166S, GA14-12166S, GA14-12166S)
- Masarykova Univerzita (MUNI/A/1087/2018, MUNI/A/1087/2018, MUNI/A/1087/2018, MUNI/A/1087/2018, MUNI/A/1087/2018)
- EC | European Regional Development Fund (CZ.02.1.01/0.0/0.0/16_019/0000868, CZ.02.1.01/0.0/0.0/16_019/0000868, CZ.02.1.01/0.0/0.0/16_019/0000868, CZ.02.1.01/0.0/0.0/16_019/0000868, CZ.02.1.01/0.0/0.0/16_019/0000868, CZ.02.1.01/0.0/0.0/16_019/0000868, CZ.02.1.01/0.0/0.0/16_019/0000868)
- Lékařská fakulta, Masarykova univerzita (P-PooL)
This publication has 78 references indexed in Scilit:
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- MdmX Is Required for p53 Interaction with and Full Induction of the Mdm2 Promoter after Cellular StressMolecular and Cellular Biology, 2012
- CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma CellsGenes & Cancer, 2010
- The Sequence Alignment/Map format and SAMtoolsBioinformatics, 2009
- Cell cycle, CDKs and cancer: a changing paradigmNature Reviews Cancer, 2009
- An essential function of the extreme C‐terminus of MDM2 can be provided by MDMXThe EMBO Journal, 2006
- The Mdm2 RING domain C‐terminus is required for supramolecular assembly and ubiquitin ligase activityThe EMBO Journal, 2006
- MDMX regulation of p53 response to ribosomal stressThe EMBO Journal, 2006
- The Hallmarks of CancerCell, 2000
- Regulation of p53 stability by Mdm2Nature, 1997